JOP20130342B1 - تكوين ثابت من بيميتركس - Google Patents

تكوين ثابت من بيميتركس

Info

Publication number
JOP20130342B1
JOP20130342B1 JOP/2013/0342A JOP20130342A JOP20130342B1 JO P20130342 B1 JOP20130342 B1 JO P20130342B1 JO P20130342 A JOP20130342 A JO P20130342A JO P20130342 B1 JOP20130342 B1 JO P20130342B1
Authority
JO
Jordan
Prior art keywords
pemetrexed formulation
stabilized pemetrexed
stabilized
formulation
acetylcysteine
Prior art date
Application number
JOP/2013/0342A
Other languages
English (en)
Inventor
Myung Jin Shin
Young Joon Park
Hong Chul Jin
Ha Yong Choi
Nak Hyun Choi
Original Assignee
Cj Cheiljedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48665454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20130342(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cj Cheiljedang Corp filed Critical Cj Cheiljedang Corp
Application granted granted Critical
Publication of JOP20130342B1 publication Critical patent/JOP20130342B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

يتعلق هذا الاختراع بتكوين بيميتركس مثبتandlsquo; وعلى الأخص فإنه يتعلق بتكوين بيميتركس مثبت يتضمن أستيل سيستاين كمضاد للتأكسد وملح سترات كمنظم.
JOP/2013/0342A 2012-11-29 2013-11-27 تكوين ثابت من بيميتركس JOP20130342B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120137375A KR101260636B1 (ko) 2012-11-29 2012-11-29 안정화된 페메트렉시드 제제

Publications (1)

Publication Number Publication Date
JOP20130342B1 true JOP20130342B1 (ar) 2021-08-17

Family

ID=48665454

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0342A JOP20130342B1 (ar) 2012-11-29 2013-11-27 تكوين ثابت من بيميتركس

Country Status (16)

Country Link
US (1) US9265832B2 (ar)
EP (1) EP2925325B1 (ar)
JP (1) JP5934448B2 (ar)
KR (1) KR101260636B1 (ar)
CN (1) CN104812392B (ar)
AR (1) AR093645A1 (ar)
BR (1) BR112015012460B1 (ar)
CL (1) CL2015001461A1 (ar)
ES (1) ES2656901T3 (ar)
HK (1) HK1212224A1 (ar)
JO (1) JOP20130342B1 (ar)
MX (1) MX355461B (ar)
PH (1) PH12015500900B1 (ar)
RU (1) RU2620341C2 (ar)
TW (1) TWI498128B (ar)
WO (1) WO2014084651A1 (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
CN105611932B (zh) * 2013-10-03 2019-02-12 富士胶片株式会社 注射液制剂及其制造方法
JP6120766B2 (ja) * 2013-12-27 2017-04-26 富士フイルム株式会社 注射液製剤及びその製造方法
KR101703980B1 (ko) 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
PL3124026T3 (pl) * 2014-03-28 2019-03-29 Fujifilm Corporation Preparat iniekcyjny i sposób jego wytwarzania
GB201418555D0 (en) * 2014-10-16 2014-12-03 Teva Gmbh Pemetrexed formulations
KR101770605B1 (ko) * 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
KR101919436B1 (ko) 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
JP6837895B2 (ja) * 2017-04-04 2021-03-03 日本化薬株式会社 医薬品溶液製剤の製造方法
US20200246263A1 (en) * 2017-08-29 2020-08-06 Fresenius Kabi Oncology Limited Stable liquid compositions of pemetrexed
KR102040034B1 (ko) 2017-12-13 2019-11-05 주식회사 아이큐어비앤피 페메트렉시드를 포함하는 경구용 약학 조성물 및 이의 제조방법
US10966982B2 (en) 2018-11-20 2021-04-06 Cipla Limited Stable pharmaceutical formulations of pemetrexed
EP4132504A1 (en) * 2020-04-09 2023-02-15 Emphascience, Inc. Methods of treatment using antifolates and pharmaceutical formulations comprising antifolates

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
CA2032695A1 (en) 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
TR200401436T4 (tr) * 2000-02-04 2004-07-21 Eli Lilly And Company Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim
US6686365B2 (en) * 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
ES2287658T3 (es) 2004-03-10 2007-12-16 Shimoda Biotech (Pty) Ltd Composiciones inyectables estables de diclofenac.
US8629152B2 (en) * 2006-08-14 2014-01-14 Sicor, Inc. Processes for the preparation of lyophilized pharmaceutically acceptable salts of pemetrexed diacid
EP2072518A1 (en) * 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stable Amorphous Form of Pemextred Disodium
WO2012015810A2 (en) 2010-07-28 2012-02-02 Eagle Pharmaceuticals, Inc. Pharmaceutical compositions containing pemetrexed having extended storage stability
KR101069128B1 (ko) 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제

Also Published As

Publication number Publication date
CN104812392A (zh) 2015-07-29
BR112015012460B1 (pt) 2022-04-05
RU2015122023A (ru) 2017-01-10
TW201434493A (zh) 2014-09-16
JP5934448B2 (ja) 2016-06-15
TWI498128B (zh) 2015-09-01
PH12015500900A1 (en) 2015-07-06
WO2014084651A1 (en) 2014-06-05
KR101260636B1 (ko) 2013-05-13
US9265832B2 (en) 2016-02-23
EP2925325B1 (en) 2017-11-01
US20150297724A1 (en) 2015-10-22
PH12015500900B1 (en) 2015-07-06
JP2016500099A (ja) 2016-01-07
EP2925325A1 (en) 2015-10-07
ES2656901T3 (es) 2018-02-28
BR112015012460A2 (ar) 2017-08-22
MX2015006325A (es) 2016-02-25
MX355461B (es) 2018-04-19
CN104812392B (zh) 2017-05-17
AR093645A1 (es) 2015-06-17
CL2015001461A1 (es) 2015-10-23
HK1212224A1 (en) 2016-06-10
EP2925325A4 (en) 2016-07-13
RU2620341C2 (ru) 2017-05-24

Similar Documents

Publication Publication Date Title
PH12015500900B1 (en) A stabilized pemetrexed formulation
PH12016500586A1 (en) Stabilized efinaconazole compositions
IL234014A (en) Cycloalkane derivatives, preparations containing them and their uses
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX361499B (es) Baricitinib deuterado.
SG11201506149SA (en) Polyetheramines based on 1,3-dialcohols
PL2984076T3 (pl) Estry i etery 2,5-tetrahydrofuranu jako plastyfikatory
CA2875305C (en) Fbxo3 inhibitors
IL242195B (en) Dicarboxylic acid compounds, compositions comprising same and uses thereof
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
MY175703A (en) Tablets with improved acceptance and good storage stability
EP2892511A4 (en) BOLAAMPHIPHILE COMPOUNDS, COMPOSITIONS AND USES THEREOF
IL237540A0 (en) Amphiphilic compounds, their preparations and uses
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IL237541A0 (en) Amphiphilic compounds, their preparations and uses
IL237538A0 (en) Amphiphilic compounds, their preparations and uses
IL237539A0 (en) Amphiphilic compounds, their preparations and uses
UA80812U (en) ETHYL 6-THIOXO-3-(2-FURYLMETHYL)-7-CYANO-1,3,4,6-2H-PYRIDO[1,2-a][1,3,5]TRIAZINE -9-CARBOXYLATE
UA86158U (en) Antibacterial agent
IN2013CH00453A (ar)
AU2012904225A0 (en) 28.8Scanfit
AU2012901213A0 (en) 28.8trackside
UA80618U (en) Use of n-steroylethanolamine as radiomodifier